Unibest
← Back to patent-cliff list

Ipatasertib

Tier C — Watch / trade

Ipatasertib

Array Biopharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:AKT1

Indications (approved):Breast cancer, 三阴性乳腺癌, Castration-resistant prostate cancer, Prostate cancer, Peritoneal cancer, Ovarian cancer, Genitourinary neoplasm, Female reproductive system cancer

Regional status

US
Phase III
2017-06-30
EU
Phase III
2017-06-30
China
Phase III
2017-06-30
Japan
Phase III
2017-06-30

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 5 · Total yield 2.1 g (Ipatasertib Dihydrochloride)
IPAT-00125026-34-0IPAT-002102029-44-7IPAT-003220041-96-3IPAT-0041189324-78-4IPAT-0051396256-89-5IPAT-0061001179-33-4IPAT-0071001269-85-7IPAT-0081001270-64-9Ipatasertib Dihydrochloride1001264-89-6API · Ipatasertib
CodeCAS No.Intermediate
IPAT-00125026-34-02-(4-chlorophenyl)acetyl chloride
IPAT-002102029-44-7Available(R)-4-benzyloxazolidin-2-one
IPAT-003220041-96-3(R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one
IPAT-0041189324-78-4tert-butyl isopropyl(methoxymethyl)carbamate
IPAT-0051396256-89-5tert-butyl ((S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)(isopropyl)carbamate
IPAT-0061001179-33-4(S)-3-((tert-butoxycarbonyl)(isopropyl)amino)-2-(4-chlorophenyl)propanoic acid
IPAT-0071001269-85-7(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-ol dihydrochloride
IPAT-0081001270-64-9tert-butyl ((S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl)(isopropyl)carbamate
Ipatasertib Dihydrochloride1001264-89-6(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one dihydrochloride

Frequently asked questions

What are the approved indications of Ipatasertib?

Approved indications include: Breast cancer, 三阴性乳腺癌, Castration-resistant prostate cancer, Prostate cancer, Peritoneal cancer, Ovarian cancer, Genitourinary neoplasm, Female reproductive system cancer.

When does the Ipatasertib patent expire?

No public expiry year is available for Ipatasertib yet; this page updates once verified.

How many synthesis routes are recorded for Ipatasertib?

1 synthesis routes are recorded; the shortest is 5 steps with 2.1 g (Ipatasertib Dihydrochloride) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ipatasertib intermediates?

1 intermediate CAS of Ipatasertib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Ipatasertib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-09